Incannex Healthcare Inc. reported continued clinical advancement for its IHL-42X treatment for obstructive sleep apnea during the fourth quarter of 2025, building on positive Phase 2 data and patient-reported outcomes. Both low- and high-dose formulations achieved statistically significant reductions in Apnoea-Hypopnoea Index compared to placebo, with maximum AHI reductions reaching 83% in the high-dose group and 79% in the low-dose cohort. Patient exit interviews revealed that 57.6% of participants reported perceived improvement in their OSA condition, with most describing the changes as meaningful to daily life through better sleep quality, reduced fatigue, and improved daily functioning.
The treatment demonstrated strong safety profiles across both dose cohorts, with no serious adverse events reported and primarily mild, transient treatment-emergent events. This safety profile reinforces IHL-42X's potential for broad clinical use if regulatory approval is achieved. Following two successful Phase 2 studies, the company has shifted focus from pure data generation toward regulatory planning and late-stage development preparation. Incannex is preparing for formal FDA interactions to define the registrational pathway, including Phase 3 design, primary and secondary endpoints, and potential expedited-review options.
Financial positioning strengthened significantly during the quarter, with the company completing an equity raise that generated $69.5 million in gross proceeds through the issuance of approximately 153.3 million shares. This brought cash and cash equivalents to $73.3 million, while management has not utilized the ATM facility since August 28, 2025. The Board further authorized a $20 million share repurchase program, providing capital management flexibility to offset dilution while maintaining funding for late-stage development programs. Additional details on the company's financial modeling and valuation approach can be found in the Stonegate Capital Partners research report.
Beyond the sleep apnea program, Incannex highlighted positive Phase 2 results for PSX-001, its psilocybin-assisted psychotherapy program for generalized anxiety disorder. The randomized, placebo-controlled study demonstrated statistically significant and clinically meaningful reductions in HAM-A scores, with 44.1% of treated patients achieving at least 50% response and 27% reaching remission. With an open Investigational New Drug application, the company is preparing multi-jurisdiction clinical studies and evaluating strategic partnerships to accelerate development and expand global access. Meanwhile, IHL-675A continues Phase 2 development for rheumatoid arthritis, representing a complementary anti-inflammatory platform asset that could broaden Incannex's long-term commercial opportunities.
The progression of these clinical programs represents significant milestones for both the pharmaceutical cannabis and psychedelic sectors, demonstrating the potential for novel treatments addressing widespread medical conditions. The sleep apnea market represents a substantial commercial opportunity given the limited effective treatment options currently available, while the anxiety disorder program addresses growing mental health needs through innovative psychedelic-assisted therapies. These developments position Incannex as a company advancing multiple high-value clinical assets while maintaining financial discipline and strategic focus on regulatory pathways and late-stage development planning.
